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Chlamydia species provoke serious infections of humans and
animals worldwide, despite extensive work to better characterize the biology of the infection and develop effective vaccines
(1–3). It is estimated that over 600 million persons are infected
with Chlamydia trachomatis, whose strains include the most
common sexually transmitted bacterial pathogen (4) as well as
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causative agents of conjunctivitis and trachoma. There are an
estimated 4 million new cases annually of genital C. trachomatis infections of the male and female within the United States
(5). In women, the most common consequence of chlamydial
genital infection is salpingitis, which can lead to tubal obstruction and infertility (2).
An important element in the design of a vaccine for the
prevention or control of chlamydial infections is a complete
understanding of the immune response to infection. Little is
known about the pathogenesis of human chlamydial infections,
and most of our knowledge of acute infection has been obtained
from animal models such as the mouse model with Chlamydia
muridarum (the mouse pneumonitis (MoPn)1 strain of C. trachomatis) (6, 7) and the guinea pig model with the Chlamydia
psittaci guinea pig inclusion conjunctivitis strain (8). In controlled studies in guinea pigs and mice (9 –11), bacteria are
initially detected in the cervical epithelium, but the pathology
ascends in most animals to the endometrium and the oviducts
within 7–9 days after intravaginal inoculation. Most of the
damage due to Chlamydia is not due to the infection itself but
to the inflammation and fibrosis that follow the infection (2).
Polymorphonuclear leukocytes are typically observed in the
cervix as early as 2 days after infection, and acute inflammation in the uterine horns and oviducts follows within 5–7 days
(2). A number of inflammatory mediators are present during
infection, including interleukin-1 (IL-1) and tumor necrosis
factor (TNF-␣), which have been detected in the Fallopian
tubes from humans infected with C. trachomatis (12) and in
secretions from Chlamydia-infected mice and guinea pigs (13–
15). TNF-␣ and other inflammatory cytokines may aid in eradicating Chlamydia infection but also may promote long term
tissue damage (14).
Contrasting with the epidemiological and pathological diversity of Chlamydia infections is the relative uniformity of the
chlamydial infectious process. All Chlamydia sp. are thought to
enter into, survive, and multiply within mucosal epithelial cells
by conserved mechanisms involving a unique obligate intracellular developmental cycle, consisting of two phases (16). The
extracellular form of Chlamydia, the elementary body (EB), is
infectious and is thought to be metabolically inert. The EB are
internalized into host epithelial cells into small vacuoles resembling endosomes, most of which avoid fusion with host cell
1
The abbreviations used are: MoPn, C. trachomatis mouse pneumonitis strain; EB, elementary body; IL, interleukin; TNF, tumor necrosis
factor; PS, phosphatidylserine; PI, propidium iodide; PMN, polymorphonuclear neutrophils; IFN, interferon.
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The BCL-2 family member BAX plays a critical role in
regulating apoptosis. Surprisingly, bax-deficient mice
display limited phenotypic abnormalities. Here we investigate the effect of BAX on infection by the sexually
transmitted pathogen, Chlamydia muridarum (the
mouse pneumonitis strain of Chlamydia trachomatis).
Baxⴚ/ⴚ cells are relatively resistant to Chlamydia-induced apoptosis, and fewer bacteria are recovered after
two infection cycles from Baxⴚ/ⴚ cells than from wildtype cells. These results suggest that BAX-dependent
apoptosis may be used to initiate a new round of infection, most likely by releasing Chlamydia-containing apoptotic bodies from infected cells that could be internalized by neighboring uninfected cells. Nonetheless,
infected Baxⴚ/ⴚ cells die through necrosis, which is normally associated with inflammation, more often than
infected wild-type cells. These studies were confirmed
in mice infected intravaginally with C. muridarum;
since the infection disappears more quickly from Baxⴚ/ⴚ
mice than from wild-type mice, secretion of proinflammatory cytokines is increased in Baxⴚ/ⴚ mice, and large
granulomas are present in the genital tract of Baxⴚ/ⴚ
mice. Taken together, these data suggest that chlamydia-induced apoptosis via BAX contributes to bacterial
propagation and decreases inflammation. Bax deficiency results in lower infection and an increased inflammatory cytokine response associated with more severe pathology.

Effect of BAX Deficiency on Chlamydia Infection

line in vitro (28), we here used Bax-deficient cells to evaluate
the role of BAX in Chlamydia-induced apoptosis and to investigate the effect of BAX-dependent apoptosis on the yield of
chlamydiae obtained from at least two infection cycles in vitro.
The availability of Bax-deficient mice also allowed us to confirm a role for BAX during genital tract infection in vivo and to
measure the host inflammatory response during infection of
wild-type and Bax-deficient mice.
EXPERIMENTAL PROCEDURES

Cells and Bacteria—The mouse pneumonitis agent (MoPn) of
C. trachomatis (C. muridarum) was from the ATCC (Manassas, VA).
Bacteria were prepared, and cells were infected as previously described
(29). The Bax⫹/⫹ (wild type), Bax⫺/⫺, Bid⫹/⫹, and Bid⫺/⫺ murine embryonic fibroblasts were described (47). All other cells and materials
were described (28, 48).
Analysis of Cell Death—Murine embryonic fibroblasts were infected
at a multiplicity of infection of 0.5. Cell death was measured by cytofluorimetry by staining detergent-permeabilized cells with PI (29, 49)
or by double-staining unpermeabilized cells with PI and annexin V (48).
Both adherent cells and cells in suspension were collected for analysis.
Effect of BAX on Infectious Activity of Chlamydia—Subconfluent
Bax⫹/⫹ and Bax⫺/⫺ cells were infected at a multiplicity of infection of
0.1, and a 10-fold excess of uninfected Bax⫹/⫹ cells was added after 24 h
of infection. After an additional 2 days of infection, the cells and supernatant were centrifuged for 60 min at 12,000 rpm in a Sorvall type GSA
rotor. The pellet was freeze-thawed three times and sonicated for 10
min in a bath sonicator at 4 °C to break cells and dissociate aggregates,
giving the final suspension of chlamydiae used to measure bacterial
yield. Serial dilutions of the chlamydial preparation were used to infect
HeLa cells on cover slips for 48 h, and the chlamydial vacuoles were
revealed with fluorescein isothiocyanate-conjugated anti-Chlamydia
monoclonal antibody, as described (29). Samples were examined with a
Zeiss fluorescence microscope attached to a cooled CCD camera. At least
10 separate fields containing an average of 200 –300 HeLa cells were
counted per sample, and the experiment was repeated on three separate
occasions.
Animal Infections—Female Bax⫹/⫹ and Bax⫺/⫺ mice on a C57BL/6
background (Jackson Laboratories, Bar Harbor, MA) were infected
intravaginally with 107 inclusion-forming units of C. muridarum. The
course of infection was monitored by periodic cervico-vaginal swabbing
of individual animals (50). Chlamydiae were isolated from swabs in
tissue culture according to standard methods, and inclusions were
visualized and enumerated by immunofluorescence (51). Results are
expressed as mean and S.E. of inclusion-forming units per ml. Experiments were repeated once, and there were five animals per experimental group. Groups of mice were sacrificed at 7 and 24 days after primary
infection or followed through day 70 and administered a challenge
infection with 107 inclusion-forming units of MoPn on day 90, 7 days
post-depo-provera treatment. Histopathology and cytokine secretion
measurements were performed as described (50). Staining of cell surface antigens and qualitative evaluation of cell populations were performed as described by Morrison and Morrison (52). Vaginal secretions
were assayed individually for cytokine or chemokine activity by enzyme-linked immunosorbent assay using commercial kits (R&D Systems, Minneapolis, MN). Antibody responses were measured in sera
from mice and assayed by enzyme-linked immunosorbent assay as
described (14).
All mice were given food ad libitum and maintained in environmentally controlled rooms with a 12/12-h light/dark cycle. All animal studies were approved by the University of Arkansas Medical Sciences’
Institutional Animal Care and Use Committee.
Statistics—Statistical comparisons between the groups of mice for
level of infection, antibody production, and cytokine production over the
course of infection were made by a two-factor (days and murine strain)
analysis of variance with the post hoc Tukey test as a multiple-comparison procedure. The Wilcoxon rank sum test was used to compare the
duration of infection in the respective groups over time. One-way analysis of variance on ranks was used to determine differences in inflammatory cell populations among the groups. All experiments were repeated at least once.
RESULTS

Effect of BAX on Host Cell Death in Vitro—We have previously shown that BAX is activated in cells infected with
Chlamydia (28). The effect of BAX activation on Chlamydia-
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lysosomes. The EB differentiate within the entry vacuole into
metabolically active reticulate bodies, which are presumably
noninfectious (17). The reticulate bodies proliferate within the
same membrane-bound vacuole and, after several divisions,
differentiate back into EB. After 2–3 days, the EB are released
from the infected cell through unknown mechanisms and begin
a new cycle of infection (16, 17).
This biphasic developmental cycle allows for multiple sites of
communication between the chlamydial pathogen and the host
cell, many of which probably play a significant role in the
pathogen-host cell relationship and thus strongly impact the
outcome of the infection. An example of such a communication
are the chlamydial signals that block and then later induce
apoptosis of the host cell. Like mycobacteria, Cryptosporidium
parvum, and the herpes virus (18 –21), Chlamydia strains protect infected cells during early stages of the infection against
apoptosis due to external stimuli (22–25) and induce apoptosis
of the host cell during later stages of the infection cycle (26 –29).
The resistance to cell death may account for the observation
that Fas- and perforin-dependent killer lymphocytes are not
able to clear the infection in mice (30). Conversely, we had
proposed that apoptosis due to the infection may be used by the
chlamydiae to exit from infected cells and propagate within the
host (29).
In mammalian cells, many of the morphological and biochemical features of apoptosis are due to activation of caspases,
which can be initiated through engagement of cell surface
receptors such as Fas (31) or following release from mitochondria of cytochrome c, which associates with the apoptosis regulator Apaf-1 and thereby activates caspase-9, which in turn
activates caspase-3 (32). Both pathways are regulated by the
BCL-2 family of proteins, which consists of antiapoptotic factors, such as BCL-2 and BCL-xL, and proapoptotic proteins,
such as BAX and BAK (33). BCL-2 proteins prevent apoptosis
by preventing the release of cytochrome c from mitochondria,
whereas BAX stimulates release of cytochrome c (34, 35). Nonetheless, caspase activation is not required for all types of cell
death (36 –38), and overexpression of BAX or BAK induces cell
death without the involvement of caspases (37, 39), suggesting
that factors other than caspases can also mediate apoptosis.
Apoptosis of Chlamydia-infected cells triggered with external ligands is blocked through inhibition of cytochrome c release and caspase-3 activation (22), whereas apoptosis induced
by the infection itself is independent of known caspases (28,
29). We have found that BAX is activated and translocates from
the cytosol to mitochondria in infected cells, and inhibition of
BAX by overexpression of BAX inhibitor-1 or BCL-2 inhibits
Chlamydia-induced apoptosis (28). Caspase-1 is not thought to
be involved in apoptosis (40), except when targeted specifically
by bacterial products secreted by Shigella flexneri or Salmonella sp. (41, 42). Nonetheless, caspase-1 is required for maturation and secretion of IL-1␤ and IL-18, and caspase-1 is activated during Chlamydia infection of monocytes and epithelial
cells (29, 43).
The preferential target tissue of sexually transmitted
chlamydial infections in females is the columnar epithelium of
the cervix (2, 17), but monocytes and macrophages can also be
infected (44) and may aid in disseminating the infection by
certain serovars of Chlamydia. Since macrophages undergoing
apoptosis secrete IL-1 (45), it is conceivable that apoptosis of
these cells during Chlamydia infection may contribute to the
inflammatory response. Conversely, cytokines such as TNF-␣
are able to induce apoptosis of some target cells (46), suggesting that the inflammation following Chlamydia infection may
also directly trigger apoptosis.
Since BAX is activated during infection of an epithelial cell
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induced apoptosis was therefore determined by infecting normal (Bax⫹/⫹) and Bax-deficient cells. The infection led to a high
level of apoptosis in Bax⫹/⫹ cells, which was observed after 1
day of infection (Fig. 1A). At the same multiplicity of infection,
the Bax deficiency resulted in a nearly 2-fold inhibition of
apoptosis during infection (Fig. 1A), suggesting that this pathway of apoptosis requires, at least partially, BAX activation.
Engagement of surface death receptors such as Fas or
TNFR1 results in cleavage of the BCL-2 family member BID,
which triggers the oligomerization of proapoptotic family members BAK and BAX, leading to cell death (47). To determine
whether BID cleavage may be required for BAX activation in
infected cells, Bid⫹/⫹ and Bid⫺/⫺ cells were infected with
C. muridarum for 2 days, and apoptosis was measured. No
difference was observed in sensitivity to apoptosis of wild-type
and Bid-deficient cells (Fig. 1A), suggesting that BAX activation is initiated within the interior of the infected cell.
Cells that are prevented from dying through apoptosis still
manage to die, but they often succumb later, dying through
necrosis (53–55). To determine quantitatively whether any in-
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FIG. 1. Effect of BAX on apoptosis and bacterial production in
vitro. A, apoptosis of wild-type, Bax⫺/⫺ cells, and Bid⫺/⫺ cells. Cells
were infected with C. muridarum for 2 days, and apoptosis of PI-labeled
detergent-permeabilized cells was measured by cytofluorimetry (see
“Experimental Procedures”). Black bar, spontaneous apoptosis of uninfected cells; white bar, apoptosis of infected cells. B, necrosis of infected
cells. Bax⫹/⫹ and Bax⫺/⫺ cells were infected for 48 h. Necrosis and
apoptosis were quantified by double-labeling unpermeabilized cells incubated with PI and annexin V (see “Experimental Procedures”). The
numbers in each quadrant refer to the percentage of cells in each
quadrant. C, chlamydial production after at least two infection cycles.
Subconfluent Bax⫹/⫹ and Bax⫺/⫺ cells were infected at a multiplicity of
infection of 0.1, and a 10-fold excess of uninfected Bax⫹/⫹ cells was
added after 24 h of infection. After an additional 2 days of infection, the
yield of chlamydiae from adherent cells and cells in suspension was
measured by titrating on uninfected HeLa cells (see “Experimental
Procedures”). IFU, inclusion-forming units.

fected cells may be necrotic, cells were infected for 2 days, and
necrosis was measured by double-labeling the cells with PI and
annexin V, which binds to phosphatidylserine (PS) that becomes exposed on the surface of dying cells. Cells labeled only
with annexin V are considered to be apoptotic, whereas cells
labeled only with PI, which have thus lost their plasma membrane integrity, are necrotic; cells labeled with both PI and
annexin V are either necrotic or late apoptotic (48). Evaluation
by cytofluorimetry showed that the Bax⫺/⫺ cells were dying
through necrosis more often than Bax⫹/⫹ cells after a 2-day
infection. Whereas 30% of the cells were apoptotic and 10%
were necrotic in the Bax⫹/⫹ population, 7% were apoptotic and
34% were necrotic in the Bax⫺/⫺ population (Fig. 1B).
Effect of BAX on Bacterial Yield in Vitro—In order to distinguish between the possibility that apoptosis may be used by the
bacteria to escape from the infected host cell, rather than by
the host cell to eliminate bacteria, Bax⫹/⫹ and Bax⫺/⫺ cells
were infected for 3 days, and the bacteria were harvested from
supernatant and infected cells. The recovered bacteria were
then used to reinfect wild-type cells, and the efficiency of infection was evaluated by immunofluorescence. A larger number
of infectious chlamydiae were recovered from the Bax⫹/⫹ than
the Bax⫺/⫺ cells (Fig. 1C), suggesting that the bacteria may use
apoptosis to exit from cells at the end of the first infection cycle
before beginning a new round of infection. To rule out the
possibility that Bax deficiency may be inhibiting growth of
intracellular chlamydiae, the number of infectious vacuoles
was also measured after a 24-h infection, before any apoptosis
is observed; the infection at 24 h was the same in either Bax⫹/⫹
or Bax⫺/⫺ cells (not shown). Since fibroblasts and epithelial
cells express a PS receptor (56) that could be used to phagocytose Chlamydia-containing apoptotic bodies, these results suggest that Chlamydia may use apoptosis to release infectious
bacteria from infected host cells in order to initiate a new
infection cycle.
Effect of BAX on Bacterial Propagation during Genital Tract
Infection—To confirm whether apoptosis has an effect on the
yield of infectious bacteria in vivo, the infection was repeated
with Bax⫹/⫹ and Bax⫺/⫺ mice. The mouse model of C. muridarum infection of the female genital tract mimics human infection (2, 9, 10) and is a useful model for Chlamydia infection and
adaptive immunity to infection. Bax-deficient mice are also
convenient for studies on Chlamydia infection, since the mice
are healthy, the levels of the antiapoptotic molecules BCL2 and
BCL-XL are unaffected, and the distribution of different lymphocyte populations (CD4⫺CD8⫺, CD4⫹CD8⫹, CD4⫹, and
CD8⫹ cells) are unaltered, compared with Bax⫹/⫹ mice (57).
The infection was less efficient and disappeared more quickly
in the Bax⫺/⫺ mice than in control Bax⫹/⫹ mice (Fig. 2), consistent with a role for BAX-dependent apoptosis in the propagation of chlamydiae in vivo.
Effect of BAX on Cytokine Secretion during Genital Tract
Infection—Prior studies in our laboratory have shown that
murine chlamydial genital tract infection induces strong production of the proinflammatory cytokine, TNF-␣, and of the
murine CXC chemokine, macrophage inflammatory protein 2
(14, 50). These responses routinely peak during the first week
of infection and decline toward base line during the second
week. Enzyme-linked immunosorbent assay measurement of
cytokines in genital tract secretions revealed similar kinetics in
the Bax⫹/⫹ and Bax⫺/⫺ mice in this study (Fig. 3). However, the
proinflammatory mediators were significantly increased during the first week of infection in the Bax⫺/⫺ mice compared
with the Bax⫹/⫹ mice. Further, we detected extremely high
levels of IFN-␥, a protein with marked antichlamydial effects,
in the Bax⫺/⫺ mice compared with Bax⫹/⫹ mice during the first
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week of infection (Fig. 3). The detection of higher levels of
inflammatory mediators in the Bax⫺/⫺ mice compared with the
Bax⫹/⫹ mice is made more significant by the fact that the
infection was much less efficient in the Bax⫺/⫺ mice. These
data are consistent with increased cell death by necrosis during
chlamydial infection in the absence of BAX.
Pathology Associated with Bax Deficiency of Infected Mice—
Histopathological and immunohistochemical examination of
genital tract tissues from mice sacrificed on day 7 of primary
infection revealed that the early inflammatory response was of
similar quality and quantity in Bax⫹/⫹ and Bax⫺/⫺ mice. Moderate to severe inflammation was detected in the endocervix
and uterine horns with a predominance of polymorphonuclear
neutrophils (PMNs) but high numbers of lymphocytes also
being seen. By immunohistochemical staining, the median inflammatory score for PMNs was 4 for Bax⫺/⫺ and 3 for Bax⫹/⫹
on day 7 (p ⫽ 0.375), and for lymphocytes it was 2.0 for Bax⫺/⫺
and for Bax⫹/⫹ (p ⫽ 0.5) (analysis of variance on ranks). Most
of the lymphocytes were CD4⫹ in both groups, with comparatively low numbers of CD8⫹ cells being found (median score for
CD4⫹ T cells ⫽ 2.0 for both groups on day 7; CD8⫹ T cells ⫽ 1).
Mild to moderate inflammation was detected in the oviducts in
both Bax⫹/⫹ and Bax⫺/⫺ mice, again with a predominance of
PMNs being found. Tissues from mice sacrificed on day 24, at a
time when infection had mostly resolved, revealed equal numbers of acute (PMNs) and chronic inflammatory cells (lymphocytes) in Bax⫹/⫹ and Bax⫺/⫺ mice. However, in 4 of 5 Bax⫺/⫺
mice, large granulomatous nodules with marked central necrosis were found scattered throughout 9 of 10 uterine horns
(Fig. 4). These nodules were seen in only 1 of 10 horns from

FIG. 3. Secretion of inflammatory proteins is increased in
Baxⴚ/ⴚ mice. TNF-␣ (A) macrophage-inflammatory protein 2 (MIP-2)
(B), and IFN-␥ (C) levels were significantly increased in the Bax⫺/⫺
(closed circles) mice compared with Bax⫹/⫹ (open circles) during the first
week of infection. Genital tract secretions were eluted from vaginal
sponges collected from individual animals before and after infection.
Results are expressed as mean and S.E. of cytokine measurements from
five animals.

Bax⫹/⫹ mice; p ⫽ 0.001, Fisher exact test). Thus, although
infection is less efficient in Bax⫺/⫺ mice, it results in greater
release of inflammatory mediators and increased chronic tissue
pathology.
Acquired Immunity in Infected Wild-type and Bax-deficient
Mice—The acquired immune response, as determined by antibody titers in serum and by resistance to reinfection, was
similar in Bax⫺/⫺ and Bax⫹/⫹ mice. Both groups demonstrated high titers of IgG2a and low titers of IgG1 (Fig. 5),
demonstrating that a TH1 response was stimulated in both
cases. Both Bax⫹/⫹ and Bax⫺/⫺ were also completely resistant to reinfection when challenged 70 days after primary
vaginal inoculation (not shown). Thus, despite the increased
release of inflammatory mediators and enhanced pathology
after primary infection in Bax⫺/⫺ mice, the absence of Bax
did not affect the quality or magnitude of the acquired immune response.
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FIG. 2. Chlamydial infection is decreased in Baxⴚ/ⴚ mice. A,
intensity and duration of primary lower genital tract infection. Female
Bax⫹/⫹ (open circles) and Bax⫺/⫺ (closed circles) mice were infected with
C. muridarum, and the course of infection was monitored by cervicovaginal swabbing. p ⬍ 0.001 by two-way analysis of variance for Bax⫹/⫹
versus Bax⫺/⫺. B, elimination of chlamydiae from wild-type and Bax⫺/⫺
mice. Results are expressed as the percentage of animals positive for
infection over time. Bax⫺/⫺ mice (closed circles) resolved the infection
more rapidly than Bax⫹/⫹ mice (open circles) with all of the Bax⫺/⫺ mice
being negative for infection by day 16. In contrast, 4 of 10 Bax⫹/⫹ mice
were still positive for infection on day 20. IFU, inclusion-forming units.
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FIG. 5. The antibody response in Baxⴙ/ⴙ and Baxⴚ/ⴚ mice. The
acquired immune response, as determined by antibody titers in serum,
was similar in both groups of mice. Black bar, IgG1 in Bax⫹/⫹; gray bar,
IgG2a in Bax⫹/⫹; dark gray bar with diagonal lines, IgG1 in Bax⫺/⫺;
light gray bar with diagonal lines, IgG2a in Bax⫺/⫺. Data are expressed
as the mean titer (log10) ⫹ S.E. for five mice at each time point. **,
significantly higher titers of IgG2a compared with IgG1 for Bax⫹/⫹ and
Bax⫺/⫺, p ⬎ 0.005. Bax⫹/⫹ and Bax⫺/⫺ titers were not significantly
different at any time point.
DISCUSSION

We here show that Bax-deficient cells are more resistant to
Chlamydia-induced apoptosis than wild-type cells. A biological
role for BAX activation is suggested by the observation that the
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FIG. 4. Large granulomas are prevalent in C. muridarum-infected Baxⴚ/ⴚ mice. A, histopathological examination of hematoxylinand eosin-stained longitudinal sections from the uterine horns of mockinfected Bax⫺/⫺ mice revealed normal endometrial type glands and an
absence of inflammation. Uteri from mock-infected Bax⫹/⫹ mice were
also normal (not shown). B, whereas the uteri from C. muridaruminfected Bax⫹/⫹ mice revealed a paucity of granulomas, the horns were
dilated with PMNs within the lumen as well as the glandular epithelium and scattered lymphocytes and plasma cells in the stroma. C, the
uterine horns from C. muridarum-infected Bax⫺/⫺ mice revealed multiple areas of granulomatous inflammation with aggregates of large
cells containing abundant eosinophilic cytoplasm consistent with histiocytes and scattered small lymphocytes.

yield of chlamydiae after two infection cycles decreases in Baxdeficient cells compared with wild-type cells. BAX could therefore contribute to exit of chlamydiae from infected cells before
initiation of a new infection cycle. The fact that C. muridarum
infection of the genital tract disappears more rapidly in Bax⫺/⫺
mice than in Bax⫹/⫹ mice also reinforces the interpretation
that BAX-dependent apoptosis could facilitate chlamydial
propagation. Finally, Bid⫺/⫺ cells are as sensitive to Chlamydia-induced apoptosis as Bid⫹/⫹ cells. Ligation of the Fas or
TNFR1 death receptors on the cell surface leads to cleavage of
BID, which activates BAX (47). The lack of involvement of BID
during Chlamydia infection suggests that BAX activation is
initiated within the host cell. Activation could be related to
infection-related metabolic stress (58), or it could be triggered
by signals released from the chlamydial vacuole via type 3
secretion mechanisms (59 – 61). Activation of BAX is clearly
advantageous for Chlamydia, and it is tempting to speculate
that other intracellular microbes may use BAX-mediated apoptosis to enhance their propagation. These results thus reveal
a novel function for a host cell proapoptotic protein, which until
now has been known to promote apoptosis through induction of
mictochondrial dysfunction and whose singular deficiency in
mice results in only minor changes to the immune system (57).
Apoptotic cells and apoptotic bodies released from dying cells
in vivo are cleared by professional scavengers such as macrophages, which express surface receptors that recognize apoptotic bodies and cells (62). Thus, PS exposed on the surface of
dying cells interacts with PS receptors on human or murine
macrophages, leading to phagocytosis of the corpses. However,
the PS receptor is also expressed on the surface of fibroblasts
and epithelial cell lines, including HeLa (derived from a carcinoma of the cervix) (56), and ubiquitously expressed molecules
such as lectins or integrins could also participate in internalization of apoptotic bodies (63). Since an antibody against the
PS receptor can block phagocytosis of apoptotic cells by fibroblasts and mammary epithelial cells (56), we propose that the
PS receptor and/or similar receptors may be used to internalize
Chlamydia-containing apoptotic cells and bodies by neighboring epithelial cells in the genital tract, thus beginning a new
round of infection.
Despite the faster clearance of bacteria in Bax⫺/⫺ mice, the
secretion of inflammatory cytokines was higher in Bax⫺/⫺ than
in wild-type mice. The secretion of TNF-␣, IFN-␥, and the
murine equivalent of IL-8, macrophage inflammatory protein
2, have been previously reported during C. muridarum infection, but until now the extent of their secretion has always
correlated with the intensity of infection (8, 13, 64). Whereas
several interpretations of these data could be envisioned, we
propose that apoptosis of infected cells in Bax⫺/⫺ mice is postponed, causing the cells to die of necrosis more often than in
Bax⫹/⫹ mice. This explanation is consistent with the observation
that more necrotic cells are observed when Bax-deficient cells are
infected in vitro than when wild-type cells are infected. Phagocytosis of apoptotic cells by macrophages leads to secretion of
anti-inflammatory cytokines such as IL-10 and transforming
growth factor-␤, but necrotic cells stimulate secretion of proinflammatory cytokines, including TNF-␣, IL-1␤, and IL-8 (65– 67).
Although these possibilities are not mutually exclusive, the resulting increase in IFN-␥ observed in Bax⫺/⫺ mice may also
contribute to their faster resolution of infection. IFN-␥ is a known
inducer of aberrant forms of Chlamydia in vitro; the cytokine
adversely affects normal growth and division of reticulate bodies
and interrupts their redifferentiation into infectious EB (68).
IFN-␥ induction of aberrant, noninfectious forms of Chlamydia
may thus contribute to reduced infection in the Bax⫺/⫺ mice.
Most of the pathological damage observed during Chlamydia
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infection is thought to be due to the inflammatory response
rather than to the microorganism itself (2, 8). The higher incidence of granulomatous nodules in the Bax⫺/⫺ mice reinforces
the notion that secretion of inflammatory cytokines by infected
epithelial cells and neighboring macrophages may be responsible for the chronic tissue damage associated with Chlamydia
infection. Although the hallmark of both ocular (trachoma) and
urogenital chlamydial infections is the development of lymphoid follicles (69 –72), granulomas have occasionally been reported in human (73), non-human primate (74), murine (75),
and veterinary disease (76). Loss of function mutations in Bax
have been reported in humans and may be associated with
increased incidence and progression of cancer (77– 80). Our
data suggest that mutations in Bax might lead to an increase in
the severity of chlamydial genital tract disease. This is the first
report of the effect of Bax mutation in an infectious disease
model.
Disordered cell death has been previously shown to have an
impact on the immune system and human disease. Thus, reduced cell death and defective clearance of apoptotic material
are thought to lead to autoimmune diseases, and macrophages
secrete proinflammatory mediators following ingestion of cells
undergoing secondary necrosis but not after ingestion of intact
apoptotic cells (62, 81, 82). We find that defects within the core
apoptotic program also lead to immunopathology. Whereas
these diseases may share the common feature that more cells
undergo necrosis when apoptosis is blocked, it is also conceivable that their pathogenesis may be multifactorial. However,
they all demonstrate clearly that blocking the signaling pathways associated with apoptosis has consequences for antigens
and infectious agents that are normally packaged into apoptotic bodies, with striking effects on host pathology.
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